Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.

[1]  Ronald N. Jones,et al.  Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. , 2009, The Journal of antimicrobial chemotherapy.

[2]  Ronald N. Jones,et al.  Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). , 2009, Diagnostic microbiology and infectious disease.

[3]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Johnson,et al.  Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years , 2009, Journal of Clinical Microbiology.

[5]  G. Sakoulas,et al.  Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses , 2008, Antimicrobial Agents and Chemotherapy.

[6]  G. Drusano,et al.  Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity , 2008, Antimicrobial Agents and Chemotherapy.

[7]  Á. Soriano,et al.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  P. Appelbaum.  Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). , 2007, International journal of antimicrobial agents.

[9]  L. Friedrich,et al.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. , 2007, The Journal of antimicrobial chemotherapy.

[10]  F. Tenover,et al.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  G. French,et al.  Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. , 2006, The Journal of antimicrobial chemotherapy.

[12]  Guiqing Wang,et al.  Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year Period , 2006, Journal of Clinical Microbiology.

[13]  Ronald N. Jones,et al.  Daptomycin Bactericidal Activity and Correlation between Disk and Broth Microdilution Method Results in Testing of Staphylococcus aureus Strains with Decreased Susceptibility to Vancomycin , 2006, Antimicrobial Agents and Chemotherapy.

[14]  Ronald N. Jones.  Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Rybak,et al.  Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model , 2004, Antimicrobial Agents and Chemotherapy.

[16]  G. Eliopoulos,et al.  Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2004, Journal of Clinical Microbiology.

[17]  L. Peterson,et al.  Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance , 1992, Clinical Microbiology Reviews.